Anhui Anke BioTech Group (300009) — Working Capital to Net Assets Ratio
Anhui Anke BioTech Group (300009) has a Working Capital to Net Assets ratio of 38.8% as of September 2025. Working capital of CN¥1.69 Billion (current assets of CN¥2.29 Billion minus current liabilities of CN¥606.63 Million) is measured against net assets of CN¥4.34 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See debt-free asset ratio of Anhui Anke BioTech Group to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Anhui Anke BioTech Group Working Capital to Net Assets (2006–2024)
This chart shows how Anhui Anke BioTech Group's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2006 to 2024. As of September 2025, the ratio stands at 38.8%, reflecting working capital of CN¥1.69 Billion against net assets of CN¥4.34 Billion CNY. Check how tangible is Anhui Anke BioTech Group's equity to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Anhui Anke BioTech Group (2006–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Anhui Anke BioTech Group from 2006 to 2024, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market cap of Anhui Anke BioTech Group.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 37.4% | CN¥1.61 Billion | CN¥4.30 Billion | CN¥2.28 Billion | CN¥667.59 Million | ▼ -0.2 pp |
| 2023 | 37.6% | CN¥1.48 Billion | CN¥3.93 Billion | CN¥2.33 Billion | CN¥847.08 Million | ▲ +1.3 pp |
| 2022 | 36.3% | CN¥1.23 Billion | CN¥3.40 Billion | CN¥1.91 Billion | CN¥675.80 Million | ▼ -8.3 pp |
| 2021 | 44.6% | CN¥1.29 Billion | CN¥2.90 Billion | CN¥1.92 Billion | CN¥626.79 Million | ▲ +4.7 pp |
| 2020 | 39.9% | CN¥1.17 Billion | CN¥2.93 Billion | CN¥1.64 Billion | CN¥472.54 Million | ▲ +0.7 pp |
| 2019 | 39.3% | CN¥1.06 Billion | CN¥2.70 Billion | CN¥1.47 Billion | CN¥414.44 Million | ▲ +23.2 pp |
| 2018 | 16.0% | CN¥322.20 Million | CN¥2.01 Billion | CN¥756.46 Million | CN¥434.26 Million | ▼ -1.7 pp |
| 2017 | 17.7% | CN¥311.85 Million | CN¥1.76 Billion | CN¥712.36 Million | CN¥400.51 Million | ▲ +10.0 pp |
| 2016 | 7.7% | CN¥109.77 Million | CN¥1.43 Billion | CN¥564.09 Million | CN¥454.32 Million | ▼ -20.6 pp |
| 2015 | 28.3% | CN¥357.97 Million | CN¥1.26 Billion | CN¥460.46 Million | CN¥102.49 Million | ▼ -7.6 pp |
| 2014 | 35.9% | CN¥277.88 Million | CN¥773.47 Million | CN¥417.68 Million | CN¥139.79 Million | ▼ -17.3 pp |
| 2013 | 53.3% | CN¥351.80 Million | CN¥660.60 Million | CN¥439.57 Million | CN¥87.77 Million | ▼ -0.5 pp |
| 2012 | 53.8% | CN¥312.00 Million | CN¥580.03 Million | CN¥383.52 Million | CN¥71.51 Million | ▼ -11.8 pp |
| 2011 | 65.6% | CN¥356.71 Million | CN¥543.88 Million | CN¥414.95 Million | CN¥58.23 Million | ▼ -6.9 pp |
| 2010 | 72.5% | CN¥378.77 Million | CN¥522.30 Million | CN¥444.32 Million | CN¥65.55 Million | ▼ -2.8 pp |
| 2009 | 75.3% | CN¥372.93 Million | CN¥495.41 Million | CN¥418.88 Million | CN¥45.95 Million | ▲ +55.9 pp |
| 2008 | 19.4% | CN¥28.80 Million | CN¥148.64 Million | CN¥103.12 Million | CN¥74.32 Million | ▲ +13.6 pp |
| 2007 | 5.8% | CN¥7.97 Million | CN¥137.09 Million | CN¥100.03 Million | CN¥92.06 Million | ▼ -14.0 pp |
| 2006 | 19.8% | CN¥24.21 Million | CN¥122.00 Million | CN¥86.93 Million | CN¥62.72 Million | — |